Key Takeaway: Werewolf Therapeutics, Inc. announced its financial results for the fourth quarter and full year of 2024. The report highlights the company's financial performance and includes a business update that outlines future strategies. This update reflects the company's ongoing commitment to growth and innovation in the biopharma sector.
Price reaction · baseline $1.225 (2025-03-10 close) · hit pre-market · clean, no other HOWL news in the window
day 0 close · peak
+2.9%
Market Sentiment Analysis
POSITIVE FACTORS
Werewolf Therapeutics reported strong financial results for Q4 and full year 2024.
The company provided a comprehensive business update indicating growth potential.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
March 11, 2025
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
WATERTOWN, Mass., March 11, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)...
Share this article:
facebook-icon
twitter-icon
linked-in-icon
Frequently Asked Questions
What financial results did Werewolf Therapeutics report?
Werewolf Therapeutics reported strong financial results for Q4 and the full year 2024.
What updates were provided by Werewolf Therapeutics?
The company provided a business update outlining its future strategies and growth potential.